

## Welcome!

Please complete the preactivity educational survey by scanning the QR code below. If you have already completed this survey, thank you — please do not respond again.



*Your input is greatly appreciated and helps guide our future educational activities.*

# Optimizing the Use of Novel Therapies for Patients with Diffuse Large B-Cell Lymphoma

**Brad S Kahl, MD**

Professor of Medicine

Washington University School of Medicine

Director, Lymphoma Program

Siteman Cancer Center

St Louis, Missouri

# Disclosures

|   |  |
|---|--|
| <b>Advisory Committees</b>                          | AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc |
| <b>Contracted Research</b>                          | BeOne, Roche Laboratories Inc  |
| <b>Data and Safety Monitoring Boards/Committees</b> | BeOne, Bristol Myers Squibb, Roche Laboratories Inc  |

# Program Steering Committee



**Jeremy S Abramson, MD, MMSc**  
Director, Center for Lymphoma  
Massachusetts General Hospital  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts



**Ann LaCasce, MD, MMSc**  
Associate Professor, Hematology and Medical Oncology  
Program Director, Dana-Farber/MGB Fellowship  
in Hematology/Oncology  
Dana-Farber Cancer Institute  
Harvard Medical School  
Boston, Massachusetts



**Brad S Kahl, MD**  
Professor of Medicine  
Washington University School of Medicine  
Director, Lymphoma Program  
Siteman Cancer Center  
St Louis, Missouri



**Matthew Lunning, DO**  
Professor  
Chief of Hematology, Interim  
Medical Director, Gene and Cellular Therapy  
Assistant Vice Chancellor for Clinical Research  
Fred and Pamela Buffett Cancer Center  
University of Nebraska Medical Center  
Omaha, Nebraska



**Manali Kamdar, MD, MBBS**  
Associate Professor  
Clinical Director of Lymphoma Services  
Morton and Sandra Saffer Endowed Chair in  
Hematology Research  
Division of Hematology, Hematologic Malignancies  
University of Colorado Cancer Center  
Aurora, Colorado

# Program Steering Committee



**Matthew Matasar, MD**  
Chief, Division of Blood Disorders  
Rutgers Cancer Institute  
Hematologist/Oncologist  
Professor  
Rutgers Robert Wood Johnson Medical School  
New Brunswick, New Jersey



**Jason Westin, MD, MS, FACP, FASCO**  
Director, Lymphoma Clinical Research  
Lead, Lymphoma and Myeloma Service Line  
Professor, Department of Lymphoma  
and Myeloma  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas



**Tycel Phillips, MD, FASCO**  
Associate Professor, Division of Lymphoma  
Department of Hematology and Hematopoietic  
Cell Transplantation  
City of Hope Comprehensive Cancer Center  
Duarte, California



**PROJECT CHAIR**  
**Neil Love, MD**  
Research To Practice  
Miami, Florida



**Gilles Salles, MD, PhD**  
Service Chief, Lymphoma Service  
Steven Greenberg Chair  
Memorial Sloan Kettering Cancer Center  
Weill Cornell Medical College  
New York, New York

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**

**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**

**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**

**Module 6: Clinician Survey Results**

# Optimizing the Use of Novel Therapies for Patients with DLBCL

## Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

## Module 2: Clinician Survey Results

## Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL

## Module 4: Clinician Survey Results

## Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL

## Module 6: Clinician Survey Results

## Key Datasets

- Morschhauser F et al. **Five-year outcomes of the POLARIX study comparing Pola-R-CHP and RCHOP in patients with diffuse large B-cell lymphoma.** *J Clin Oncol* 2025 December 10;43(35):3698-705.
- Trněný M et al. Analysis of **peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.** *Blood Adv* 2025 July 8;9(13):3263-7.
- Vitolo U et al. **frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.** ASCO 2022;Abstract TPS7590.
- Sehn LH et al. **ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).** ASCO 2021;Abstract TPS7572.

# Phase III POLARIX Study Design

## Eligibility Criteria:


- Previously untreated LBCL
- Aged 18-80 years
- IPI score 2-5
- ECOG PS 0-2

## Primary endpoint:

Investigator-assessed PFS


## Secondary endpoints:

Investigator-assessed EFS, ORR, OS




LBCL = large B-cell lymphoma; PFS = progression-free survival; EFS = event-free survival; ORR = overall response rate; OS = overall survival

## Phase III POLARIX: 5-Year PFS (Global Population)




## Phase III POLARIX: 5-Year OS (Global Population)



# Phase III POLARIX: Adverse Events of Interest


| Patients, n (%)                           | Pola-R-CHP<br>(n=495) | R-CHOP<br>(n=498) |
|---|-----------------------|-------------------|
| <b>Peripheral neuropathy</b>              |                       |                   |
| All grade                                 | 249 (50.3)            | 261 (52.4)        |
| Grade 3–5                                 | 7 (1.4)               | 5 (1.0)           |
| Resolved <sup>a</sup>                     | 170 (68.3)            | 195 (74.7)        |
| Ongoing/Unresolved <sup>b</sup>           | 79 (31.7)             | 66 (25.3)         |
| <b>Neutropenia</b>                        |                       |                   |
| All grade                                 | 240 (48.5)            | 228 (45.8)        |
| Grade 3–5                                 | 216 (43.6)            | 205 (41.2)        |
| <b>Infections</b>                         |                       |                   |
| All grade                                 | 237 (47.9)            | 219 (44.0)        |
| Grade 3–5                                 | 75 (15.2)             | 66 (13.3)         |
| <b>Anemia</b>                             |                       |                   |
| All grade                                 | 165 (33.3)            | 150 (30.1)        |
| Grade 3–5                                 | 56 (11.3)             | 49 (9.8)          |
| <b>Thrombocytopenia</b>                   |                       |                   |
| All grade                                 | 89 (18.0)             | 86 (17.3)         |
| Grade 3–5                                 | 32 (6.5)              | 31 (6.2)          |
| <b>Cardiac arrhythmias</b>                |                       |                   |
| All grade                                 | 18 (3.6)              | 26 (5.2)          |
| Grade 3–5                                 | 3 (0.6)               | 5 (1.0)           |
| <b>Secondary malignancies<sup>c</sup></b> |                       |                   |
| All grade                                 | 5 (1.0)               | 12 (2.4)          |
| Grade 3–5                                 | 5 (1.0)               | 9 (1.8)           |



## Phase III POLARIX: Peripheral Neuropathy

# Rationale for Tafasitamab and Lenalidomide Combination Therapy

Figure 1. Mode of action of tafasitamab plus lenalidomide



## Tafasitamab (Fc-enhanced, anti-CD19 mAb)<sup>11</sup>

Affinity-matured  
CD19 binding site

- ADCC ↑
- ADCP ↑
- Direct cell death




## Lenalidomide<sup>15</sup>

- T-cell and NK-cell proliferation/activation
- Direct antitumor activity

Adapted from Salles et al. Expert Opin Biol Ther 2021.<sup>12</sup>  
ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cell-mediated phagocytosis; mAb, monoclonal antibody; NK,

# Phase III frontMIND Study Design



# The Manufacturer Announces Positive Topline Results from Pivotal Study of Tafasitamab As a First-Line Treatment for DLBCL

Press Release: January 5, 2026

“[The manufacturer] today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age.


The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; *p*-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed.

Based on these positive results, [the manufacturer] expects to file a supplemental Biologics License Application (sBLA) for tafasitamab for the first-line treatment of adults with newly diagnosed DLBCL in the first half of 2026. The frontMIND data will be submitted for presentation at an upcoming scientific meeting.”

## Studies Supporting the ESCALADE Study

- **ACCEPT — Davies et al. ASH 2020**
  - “There is a strong rationale for combining A with R-CHOP in pts with untreated DLBCL, and safety of A + R-CHOP has been shown in a phase 1b/2 study”
- **PHOENIX — Younes et al. *J Clin Oncol* 2019;37:1285-9.**
  - “In untreated non-GCB DLBCL pts, [PHOENIX] showed that addition of the BTKi ibrutinib to R-CHOP (R-CHOP-I) did not improve outcomes in the intent-to-treat population. However, pts age <60y treated with R-CHOP-I had significantly improved progression-free survival (PFS) and overall survival (OS) compared with those receiving R-CHOP alone.”

# Phase III ESCALADE (ACE-LY-312) Study Design



## Primary endpoint:

PFS

## Secondary endpoints:

EFS, CR rate, OS, pharmacokinetics, safety

\*All patients will receive primary prophylaxis with G-CSF accompanying all R-CHOP cycles.

GCB = germinal center B-cell-like; CR = complete response; G-CSF = granulocyte-colony stimulating factor

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**









**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**

**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**









**Module 6: Clinician Survey Results**

# Which first-line therapy would you generally recommend for an otherwise healthy patient with Stage IV germinal center B-cell (GCB)-type diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 3?









|  | 65-year-old                 | 80-year-old                              |
|--|-----------------------------|--|
|  <b>Dr Abramson</b>   | R-CHP + polatuzumab vedotin | Dose-reduced R-CHP + polatuzumab vedotin |
|  <b>Dr Kahl</b>       | R-CHOP                      | R-mini-CHOP                              |
|  <b>Dr Kamdar</b>     | R-CHP + polatuzumab vedotin | R-mini-CHOP                              |
|  <b>Dr LaCasce</b>    | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  <b>Dr Matasar</b>    | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  <b>Dr Phillips</b>  | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  <b>Prof Salles</b> | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  <b>Dr Westin</b>   | R-CHOP                      | R-mini-CHOP                              |

R-CHP = rituximab/cyclophosphamide/doxorubicin/prednisone; R-mini-CHOP = rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (attenuated)

Which first-line therapy would you generally recommend for an otherwise healthy patient with Stage IV activated B-cell (ABC)-type DLBCL with an IPI score of 3?

|   | 65-year-old                 | 80-year-old                              |
|---|-----------------------------|--|
|  Dr Abramson   | R-CHP + polatuzumab vedotin | Dose-reduced R-CHP + polatuzumab vedotin |
|  Dr Kahl       | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Dr Kamdar     | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Dr LaCasce    | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Dr Matasar    | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Dr Phillips  | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Prof Salles | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |
|  Dr Westin   | R-CHP + polatuzumab vedotin | R-mini-CHP + polatuzumab vedotin         |

A 75-year-old woman with a history of congestive heart failure and a LVEF of 45% presents with Stage IV DLBCL with an IPI of 3. Which initial therapy would you most likely recommend if she had the DLBCL molecular subtype below?

|   | GCB-type              | ABC-type, high-risk                  |
|---|-----------------------|--------------------------------------|
|  Dr Abramson   | R-CHOP + dexrazoxane  | Pola-R-CHP + dexrazoxane             |
|  Dr Kahl       | R-CEOP                | R-mini-CHP + polatuzumab vedotin     |
|  Dr Kamdar     | Dose-adjusted R-EPOCH | Pola-R-CHP + dexrazoxane             |
|  Dr LaCasce    | R-GCVP                | Pola-R-CGP                           |
|  Dr Matasar    | R-GCVP                | R-GCVP                               |
|  Dr Phillips  | Dose-adjusted R-EPOCH | R-CP + Pola + infusional doxorubicin |
|  Prof Salles | R-GCVP                | R-mini-CGemP-Pola                    |
|  Dr Westin   | R-CEOP                | RCEP-Pola                            |

R = rituximab; C = cyclophosphamide; E = etoposide; O = vincristine; P = prednisone; G = gemcitabine; V = vincristine; Pola = polatuzumab vedotin

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**

**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**


**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**

**Module 6: Clinician Survey Results**

# Key Datasets

- Duell J et al. **Tafasitamab** for patients with **relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings** in the phase II **L-MIND** study. *Haematologica* 2024 February 1;109(2):553-66.
- Arias DA et al. **CD19 expression** persists in **diffuse large B-cell lymphoma** patient biopsies after treatment with **tafasitamab**. EHA 2024;Abstract P1234.
- Kim TM et al. **Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma**. ASCO 2025;Abstract 7046.
- Dickinson MJ et al. **Glofitamab** for **relapsed or refractory diffuse large B-cell lymphoma**. *N Engl J Med* 2022 December 15;387(24):2220-31.
- Karimi YH et al. **3-year update** from the **Epcore NHL-1 trial: Epcoritamab** leads to deep and durable responses in **relapsed or refractory large B-cell lymphoma**.. ASH 2024;Abstract 4480.
- Abramson JS et al. **Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial**. *Lancet* 2024 November 16;404(10466):1940-54.

# Phase II L-MIND Study Design




HDT = high-dose therapy; ASCT = autologous stem cell transplant; SD = stable disease; DoR = duration of response

## Phase II L-MIND: Efficacy Outcomes (Primary, 3-Year, 5-Year Analyses)


| Characteristics                  | Primary analysis         | 3-year follow-up         | Final 5-year data        | 5-year data for patients with 1 prior line of therapy, N=40 | 5-year data for patients with ≥2 prior lines of therapy, N=40 |
|----------------------------------|--------------------------|--------------------------|--------------------------|---|---|
| Data cut-off date                | Nov 30, 2018             | Oct 30, 2020             | Nov 14, 2022             | Nov 14, 2022  | Nov 14, 2022  |
| Best ORR, N (%)<br>[95% CI]      | 48 (60.0)<br>[48.4-70.9] | 46 (57.5)<br>[45.9-68.5] | 46 (57.5)<br>[45.9-68.5] | 27 (67.5)<br>[50.9-81.4]                                    | 19 (47.5)<br>[31.5-63.9]                                      |
| CR rate, N (%)<br>[95% CI]       | 34 (42.5)<br>[32.0-54.0] | 32 (40.0)<br>[29.2-51.6] | 33 (41.3)<br>[30.4-52.8] | 21 (52.5)<br>[36.1-68.5]                                    | 12 (30.0)<br>[16.6-46.5]                                      |
| PR rate, N (%)<br>[95% CI]       | 14 (17.5)<br>[10.0-28.0] | 14 (17.5)<br>[9.9-27.6]  | 13 (16.3)<br>[8.9-26.2]  | 6 (15.0)<br>[5.7-29.8]                                      | 7 (17.5)<br>[7.3-32.8]  |
| Median DoR in months<br>[95% CI] | 21.7<br>[21.7-NR]        | 43.9<br>[26.1-NR]        | NR<br>[33.8-NR]          | NR<br>[9.1-NR]  | NR<br>[26.1-NR]   |
| Median PFS in months<br>[95% CI] | 12.1<br>[5.7-NR]         | 11.6<br>[6.3-45.7]       | 11.6<br>[5.7-45.7]       | 23.5<br>[7.4-NR]  | 7.6<br>[2.7-45.5]   |
| Median OS in months<br>[95% CI]  | NR<br>[18.3-NR]          | 33.5<br>[18.3-NR]        | 33.5<br>[18.3-NR]        | NR<br>[24.6-NR]   | 15.5<br>[8.6-45.5]  |

ORR: objective response rate; 95% CI: 95% confidence interval; CR: complete response; PR: partial response; DoR: duration of response; NR: not reached; PFS: progression-free survival; OS: overall survival.

# Phase II L-MIND: Adverse Events of Special Interest




# Phase III firmMIND Study Design



Estimated completion (primary): 2026-04-01

# AZD0486: A CD19 x CD3 Bispecific T-Cell Engager



## Phase I AZD0486 Study: Responses by Target Dose ( $\geq 7.2$ mg)

|               | Overall (N=58) |     |         | CAR-T Naive (n=31) |     |         | CAR-T Exposed (n=27) |     |         |
|---------------|----------------|-----|---------|--------------------|-----|---------|----------------------|-----|---------|
|               | n              | ORR | CR rate | n                  | ORR | CR rate | n                    | ORR | CR rate |
| <b>7.2 mg</b> | 24             | 46% | 33%     | 9                  | 67% | 44%     | 15                   | 33% | 27%     |
| <b>15 mg</b>  | 26             | 62% | 39%     | 16                 | 75% | 38%     | 10                   | 40% | 40%     |
| <b>25 mg</b>  | 8              | 75% | 63%     | 6                  | 83% | 67%     | 2                    | 50% | 50%     |

# Phase I AZD0486 Study: Safety






| Most common AEs (≥15%)                   | Any grade | Grade 3 | Grade 4 |
|--|-----------|---------|---------|
| CRS                                      | 42 (49)   | 0       | 0       |
| Infections and infestations <sup>b</sup> | 39 (45)   | 10 (12) | 1 (1)   |
| Neutropenia                              | 29 (34)   | 9 (10)  | 15 (17) |
| Constipation                             | 21 (24)   | 0       | 0       |
| Anemia                                   | 20 (23)   | 14 (16) | 0       |
| Fatigue                                  | 20 (23)   | 3 (3)   | 0       |
| ICANS                                    | 17 (20)   | 5 (6)   | 0       |
| Hypogammaglobulinemia                    | 16 (19)   | 0       | 0       |
| Nausea                                   | 16 (19)   | 1 (1)   | 0       |
| Diarrhea                                 | 14 (16)   | 0       | 0       |
| Pyrexia                                  | 13 (15)   | 0       | 0       |

Values are n (%).  
<sup>a</sup>All patients eventually received TD.  
<sup>b</sup>Grouped by system organ class. One grade 5 event reported (pneumonia). COVID-19 infections reported in 9 (10%) patients (n=3 grade 1; n=6 grade 2).

AEs = adverse events; CRS = cytokine release syndrome; ICANS = immune effector cell-associated neurotoxicity syndrome

| AZD0486 2SUD cohort (n=70), n (%) | Grade 1 | Grade 2 | Grade 3 | Grade ≥4 | Total   |
|-----------------------------------|---------|---------|---------|----------|---------|
| CRS                               | 30 (43) | 4 (6)   | 0       | 0        | 34 (49) |
| ICANS                             | 4 (6)   | 6 (9)   | 4 (6)   | 0        | 14 (20) |

# Bispecifics for DLBCL

|        | BLINATUMOMAB  | MOSUNETUZUMAB   | EPCORITAMAB   | GLOFITAMAB  | ODRONEXTAMAB  |
|--------|---|---|---|---|---|
| TARGET | CD3xCD19  | CD3xCD20  | CD3xCD20  | CD3x(CD20) <sub>2</sub>   | CD3xCD20  |
| DESIGN |    |   |    |    |    |
|        | <ul style="list-style-type: none"> <li>• Monovalent CD3 and monovalent CD19 binding</li> <li>• Two murine scFv-joined by a glycine-serine linker</li> </ul> | <ul style="list-style-type: none"> <li>• Monovalent CD3 and monovalent CD20 binding</li> <li>• Humanized mouse IgG1-based antibody</li> </ul> | <ul style="list-style-type: none"> <li>• Monovalent CD3 and monovalent CD20 binding</li> <li>• Humanized mouse IgG1-based antibody</li> </ul> | <ul style="list-style-type: none"> <li>• Monovalent CD3 and bivalent CD20 binding</li> <li>• Humanized mouse IgG1-based antibody</li> </ul> | <ul style="list-style-type: none"> <li>• Monovalent CD3 and monovalent CD20 binding</li> <li>• Fully human IgG4-based antibody</li> </ul> |


# Glofitamab for R/R DLBCL Study: Efficacy (IRC- and Investigator-Assessed)

| Outcome  | Assessment According to Independent Review Committee (N=155) | Assessment According to Investigator (N=155) |
|--|--|--|
| <b>Complete response</b>                               |  |  |
| No. of patients with response                          | 61   | 58   |
| Percentage of patients (95% CI)                        | 39 (32–48)   | 37 (30–46)                                   |
| <b>Objective response</b>                              |  |  |
| No. of patients with response                          | 80   | 89   |
| Percentage of patients (95% CI)                        | 52 (43–60)   | 57 (49–65)                                   |
| <b>Duration of complete response†</b>                  |  |  |
| Median (95% CI) — mo                                   | NR (16.8–NR)   | 19.8 (18.2–NR)                               |
| Complete response at 12 mo (95% CI) — %                | 78 (64–91)   | 72 (59–86)                                   |
| <b>Duration of objective response‡</b>                 |  |  |
| Median (95% CI) — mo                                   | 18.4 (13.7–NR)   | 10.4 (6.8–NR)                                |
| Objective response at 12 mo (95% CI) — %               | 64 (51–76)   | 49 (37–61)                                   |
| Median time to first complete response (range) — days† | 42 (31–308)  | 43 (31–274)                                  |
| <b>Progression-free survival</b>                       |  |  |
| Median (95% CI) — mo                                   | 4.9 (3.4–8.1)  | 3.8 (3.3–5.4)                                |
| Alive without progression at 12 mo (95% CI) — %        | 37 (29–46)   | 30 (22–38)                                   |
| <b>Overall survival</b>                                |  |  |
| Median (95% CI) — mo                                   | —  | 11.5 (7.9–15.7)                              |
| Alive at 12 mo (95% CI) — %                            | —  | 50 (41–58)                                   |



# Glofitamab for R/R DLBCL: Safety

| n (%) <sup>*</sup>                        | N=154                |
|---|----------------------|
| Median no. of cycles received (range)     | 5 (1–13)             |
| Median relative dose intensity, % (range) | 100 (94–100)         |
| AE  | 152 (98.7)           |
| Related AE                                | 140 (90.9)           |
| Grade 3–4 AE                              | 87 (56.5)            |
| Related AE                                | 64 (41.6)            |
| Serious AE                                | 73 (47.4)            |
| Related AE                                | 46 (29.9)            |
| Grade 5 (fatal AE)                        | 8 (5.2) <sup>†</sup> |
| Related AE                                | 0                    |
| AE leading to treatment discontinuation   | 14 (9.1)             |
| Related AE                                | 5 (3.2)              |



**Glofitamab was well tolerated, with a favorable safety profile**

<sup>\*</sup>unless otherwise specified; <sup>†</sup>COVID-19/COVID-19 pneumonia (n=5); sepsis (n=2); delirium (n=1); <sup>‡</sup>includes neutrophil count decreased; <sup>§</sup>includes platelet count decreased; <sup>¶</sup>pyrexia events separate from CRS.

# Phase II EPCORE NHL-1 Study Design


## Dose expansion

### Key inclusion criteria:

- R/R CD20<sup>+</sup> LBCL
  - DLBCL (*de novo* or transformed)
  - “Double-” or “triple-hit” DLBCL<sup>a</sup>
  - PMBCL
  - HGBCL
  - FL G3B
- ECOG PS 0–2
- ≥2 prior lines of antineoplastic therapy, incl ≥1 anti-CD20 mAb
- Measurable disease by CT/MRI
- Prior CAR T therapy allowed

**Median follow-up: 37.1 mo**


Step-up dosing<sup>b</sup>




- **Primary endpoint:** ORR per Lugano criteria<sup>1</sup>
- **Key secondary endpoints:** CR, DOR, DOCR, PFS, OS, TTNT, MRD- rate, and safety/tolerability
- Exploratory MRD analyses of ctDNA were performed using the clonoSEQ<sup>®</sup> NGS assay<sup>c</sup>

PMBCL = primary mediastinal B-cell lymphoma; HGBCL = high-grade B-cell lymphoma; FL = follicular lymphoma; DOCR = duration of complete response; TTNT = time to next treatment; MRD = minimal residual disease; ctDNA = circulating tumor DNA

# Phase II EPCORE NHL-1: Responses



# Phase II EPCORE NHL-1: Overall Survival



# The Manufacturer Announces Topline Results for Epcoritamab from Phase III EPCORE DLBCL-1 Trial in Patients with R/R DLBCL


Press Release: January 16, 2026

“On January 16, 2026, [the manufacturer] today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92]). Improvements were observed in complete response rates (CRR), duration of response (DoR), and time to next treatment among patients treated with epcoritamab. The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI 0.77 to 1.20]).

EPCORE DLBCL-1 is the first Phase 3 study to demonstrate improvement in PFS in patients with R/R DLBCL who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy (73% had received two or more prior lines) who were ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT).

The data will be submitted for presentation at a future medical meeting, and [the manufacturers] will engage global regulatory authorities to determine next steps.”

# Phase III STARGLO Study Design




**Primary endpoint:**

Overall survival

**Secondary endpoints:**


Progression-free survival, ORR, DoR

# Phase III STARGLO: Overall Survival (Primary Endpoint)




|  | R-GemOx (n=91)   | Glofit-GemOx (n=183) | p value*  |
|--|------------------|----------------------|-----------|
| <b>Primary endpoint</b>                |                  |                      |           |
| Investigator-assessed overall survival | ..               | ..                   | ..        |
| HR                                     | ..               | 0.62 (0.43-0.88)†    | p=0.0064† |
| Median, months                         | 12.9 (7.9-18.5)  | 25.5 (18.3-NE)       | ..        |
| 24-month rate, %                       | 33.5 (22.2-44.9) | 52.8 (44.8-60.7)     | ..        |

# Phase III STARGLO: Progression-Free Survival



|   | R-GemOx (n=91)   | Glofit-GemOx (n=183) | p value*       |
|---|------------------|----------------------|----------------|
| <b>Secondary endpoints</b>                      |                  |                      |                |
| IRC-assessed progression-free survival          | ..               | ..                   | ..             |
| HR  | ..               | 0.40 (0.28-0.57)†    | $p < 0.0001$ † |
| Median, months                                  | 3.6 (2.5-7.1)    | 13.8 (8.7-20.5)      | ..             |
| 12-month rate, %                                | 25.2 (13.6-36.9) | 51.7 (44.0-59.4)     | ..             |
| Investigator-assessed progression-free survival | ..               | ..                   | ..             |
| HR  | ..               | 0.32 (0.23-0.45)†    | $p < 0.0001$ † |
| Median, months                                  | 2.7 (2.2-5.3)    | 14.4 (9.2-24.6)      | ..             |
| 12-month rate, %                                | 20.5 (10.7-30.3) | 53.2 (45.5-60.9)     | ..             |

# Phase III STARGLO: Responses



|   | R-GemOx (n=91)   | Glofit-GemOx (n=183) | p value*  |
|---|------------------|----------------------|-----------|
| <b>Secondary endpoints</b>                      |                  |                      |           |
| IRC-assessed best overall response‡, %          | ..               | ..                   | ..        |
| Objective response                              | 40.7 (30.5-51.5) | 68.3 (61.0-75.0)     | p<0.0001† |
| Complete response                               | 25.3 (16.8-35.5) | 58.5 (51.0-65.7)     | p<0.0001† |
| Investigator-assessed best overall response‡, % | ..               | ..                   | ..        |
| Objective response                              | 37.4 (27.4-48.1) | 69.9 (62.7-76.5)     | p<0.0001† |
| Complete response                               | 23.1 (14.9-33.1) | 57.4 (49.9-64.6)     | p<0.0001† |
| IRC-assessed duration of complete response      | n=23             | n=107                | ..        |
| HR  | ..               | 0.59 (0.25-1.35)§    | p=0.20§   |
| Median, months                                  | 24.2 (6.9-NE)    | NE (NE-NE)           | ..        |
| IRC-assessed duration of objective response     | n=37             | n=125                | ..        |
| HR  | ..               | 0.57 (0.30-1.10)§    | p=0.089§  |
| Median, months                                  | 10.3 (6.5-NE)    | NE (17.6-NE)         | ..        |

# Phase III STARGLO: Safety

|  | R-GemOx (n=88) | Glofit-GemOx (n=180) |
|--|----------------|----------------------|
| Any adverse event  | 84 (96%)       | 180 (100%)           |
| Most common adverse event ( $\geq 30\%$ patients in either group)        |                |                      |
| Thrombocytopenia*  | 42 (48%)       | 87 (48%)             |
| CRS†   | NA             | 76 (44%)†            |
| Neutropenia‡   | 27 (31%)       | 76 (42%)             |
| Anaemia  | 19 (22%)       | 73 (41%)             |
| Nausea   | 35 (40%)       | 71 (39%)             |
| Peripheral neuropathy§   | 23 (26%)       | 64 (36%)             |
| Diarrhoea  | 24 (27%)       | 62 (34%)             |
| Aspartate transferase increased  | 17 (19%)       | 59 (33%)             |
| Alanine transaminase increased   | 19 (22%)       | 57 (32%)             |
| Any glofitamab-related or rituximab-related adverse event                | 58 (66%)       | 149 (83%)            |
| Any grade $\geq 3$ adverse event   | 36 (41%)       | 140 (78%)            |
| Any glofitamab-related or rituximab-related grade $\geq 3$ adverse event | 20 (23%)       | 85 (47%)             |
| Any serious adverse event  | 15 (17%)       | 98 (54%)             |
| Any glofitamab-related or rituximab-related serious adverse event        | 7 (8%)         | 62 (34%)             |
| Any adverse event of special interest                                    | 69 (78%)       | 176 (98%)            |
| CRS†   | NA             | 76 (44%)†            |
| Grade 1  | NA             | 54 (31%)†            |
| Grade 2  | NA             | 18 (11%)†            |
| Grade 3  | NA             | 4 (2%)†              |
| Neurological adverse event (grade $\geq 2$ )                             | 11 (13%)       | 55 (31%)             |
| Serious infections   | 11 (13%)       | 46 (26%)             |
| Febrile neutropenia  | 1 (1%)         | 6 (3%)               |
| Tumour flare (grade $\geq 2$ )   | 1 (1%)         | 1 (1%)               |
| Any grade 5 adverse event  | 4 (5%)         | 15 (8%)              |

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**









**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**

**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**









**Module 6: Clinician Survey Results**

Regulatory and reimbursement issues aside, which second-line therapy would you generally recommend for an older (85-year-old) patient with DLBCL who experienced disease relapse 18 months after first-line R-CHOP and who was ...

|   | CAR T eligible but transplant ineligible | Transplant <i>and</i> CAR T ineligible                        |
|---|--|---|
|  Dr Abramson   | CAR T-cell therapy                       | Mosunetuzumab/polatuzumab vedotin                             |
|  Dr Kahl       | CAR T-cell therapy                       | Mosunetuzumab/polatuzumab vedotin                             |
|  Dr Kamdar     | CAR T-cell therapy                       | Tafasitamab/lenalidomide or glofitamab/GemOx                  |
|  Dr LaCasce    | CAR T-cell therapy                       | Mosunetuzumab/polatuzumab vedotin                             |
|  Dr Matasar    | CAR T-cell therapy                       | Glofitamab/GemOx  |
|  Dr Phillips  | Mosunetuzumab/polatuzumab vedotin        | Mosunetuzumab/polatuzumab vedotin                             |
|  Prof Salles | Glofitamab/GemOx                         | Glofitamab/GemOx  |
|  Dr Westin   | CAR T-cell therapy                       | Tafasitamab/lenalidomide or mosunetuzumab/polatuzumab vedotin |

GemOx = gemcitabine/oxaliplatin

Regulatory and reimbursement issues aside, which third-line therapy would you generally recommend for a 65-year-old patient with DLBCL who received first-line R-CHOP and subsequently experienced disease progression on second-line CAR T-cell therapy?

|   |                    |   |
|---|--------------------|---|
|    | <b>Dr Abramson</b> | <b>Glofitamab/GemOx</b>                                   |
|    | <b>Dr Kahl</b>     | <b>Glofitamab</b>   |
|    | <b>Dr Kamdar</b>   | <b>Glofitamab</b>   |
|    | <b>Dr LaCasce</b>  | <b>Glofitamab</b>   |
|    | <b>Dr Matasar</b>  | <b>Polatumumab vedotin/R-GemOx</b>                        |
|    | <b>Dr Phillips</b> | <b>Glofitamab/polatumumab vedotin</b>                     |
|  | <b>Prof Salles</b> | <b>Glofitamab/GemOx or polatumumab vedotin/glofitamab</b> |
|  | <b>Dr Westin</b>   | <b>Glofitamab/GemOx or polatumumab vedotin/glofitamab</b> |

R-GemOx = rituximab/gemcitabine/oxaliplatin

Regulatory and reimbursement issues aside, which third-line therapy would you generally recommend for a 65-year-old patient with DLBCL who received first-line polatuzumab vedotin/R-CHP and subsequently experienced disease progression on second-line CAR T-cell therapy?



**Dr Abramson**

**Glofitamab/GemOx**



**Dr Kahl**

**Glofitamab**



**Dr Kamdar**

**Glofitamab**



**Dr LaCasce**

**Glofitamab**



**Dr Matasar**

**Loncastuximab tesirine**



**Dr Phillips**

**Glofitamab/GemOx**



**Prof Salles**

**Glofitamab/GemOx**



**Dr Westin**

**Glofitamab/GemOx**

Regulatory and reimbursement issues aside, which third-line therapy would you generally recommend for an 85-year-old patient with DLBCL who received first-line R-mini-CHOP and subsequently experienced disease progression on second-line polatuzumab vedotin with bendamustine/rituximab (BR)?



**Dr Abramson**

**Glofitamab**



**Dr Kahl**

**Glofitamab**



**Dr Kamdar**

**Glofitamab**



**Dr LaCasce**

**Glofitamab**



**Dr Matasar**

**Glofitamab/GemOx**



**Dr Phillips**

**Glofitamab or epcoritamab**



**Prof Salles**


**Glofitamab/GemOx**











**Dr Westin**

**Glofitamab or epcoritamab**









Assuming equal access, which bispecific antibody would you prefer to use when administering one of these agents as monotherapy for your patients with R/R DLBCL?

|   |                    |                      |
|---|--------------------|----------------------|
|    | <b>Dr Abramson</b> | <b>Glofitamab</b>    |
|    | <b>Dr Kahl</b>     | <b>Glofitamab</b>    |
|    | <b>Dr Kamdar</b>   | <b>Glofitamab</b>    |
|    | <b>Dr LaCasce</b>  | <b>Glofitamab</b>    |
|    | <b>Dr Matasar</b>  | <b>Glofitamab</b>    |
|    | <b>Dr Phillips</b> | <b>No preference</b> |
|  | <b>Prof Salles</b> | <b>Glofitamab</b>    |
|  | <b>Dr Westin</b>   | <b>Glofitamab</b>    |

# Based on the published literature and your clinical experience, would you like to have access to surovatamig for your patients with R/R DLBCL today?

|  |  |
|--|--|
|  <b>Dr Abramson</b>   | <b>Yes, for patients with CD20-negative disease</b>  |
|  <b>Dr Kahl</b>       | <b>Yes, for patients who are ineligible for CAR T or who have lost CD20 expression and are ineligible for glofitamab and epcoritamab</b> |
|  <b>Dr Kamdar</b>     | <b>Yes, for CAR T-ineligible pts in the second-line setting</b>  |
|  <b>Dr LaCasce</b>    | <b>Yes, for patients who are ineligible for CD19 CAR T</b>   |
|  <b>Dr Matasar</b>    | <b>No</b>  |
|  <b>Dr Phillips</b>   | <b>Yes, after CAR T-cell therapy</b>   |
|  <b>Prof Salles</b> | <b>Yes, for patients with PD on CD3 x CD20 combinations or monotherapy, and for those with CD20-negative disease</b>                     |
|  <b>Dr Westin</b>   | <b>Yes, for patients with CD20 loss and non-CAR T eligible</b>   |

# If surovatamig were granted regulatory approval, would you employ a CD20 x CD3 bispecific antibody and surovatamig in sequence for the same patient with R/R DLBCL?

|   |                    |              |
|---|--------------------|--------------|
|    | <b>Dr Abramson</b> | <b>Yes</b>   |
|    | <b>Dr Kahl</b>     | <b>Yes</b>   |
|    | <b>Dr Kamdar</b>   | <b>Yes</b>   |
|    | <b>Dr LaCasce</b>  | <b>Maybe</b> |
|    | <b>Dr Matasar</b>  | <b>Yes</b>   |
|    | <b>Dr Phillips</b> | <b>Yes</b>   |
|  | <b>Prof Salles</b> | <b>Yes</b>   |
|  | <b>Dr Westin</b>   | <b>Yes</b>   |

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**

**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**

**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**

**Module 6: Clinician Survey Results**

# Key Datasets

- Sehn LH et al. **Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (ext) study.** ASH 2022;Abstract 4260.
- Matasar M et al. **Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial.** EHA 2025;Abstract S101.
- Budde LE et al. **Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: Primary results of the phase III SUNMO trial.** *J Clin Oncol* 2025 December 20;43(36):3799-811.
- Kim JA et al. **Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.** ASCO 2024;Abstract LBA7005.
- Caimi PF et al. **Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study.** *Haematologica* 2024 April 1;109(4):1184-93.
- Carlo-Stella C et al. **Updated safety run-in results from LOTIS-5: A phase 3, randomized trial of loncastuximab tesirine with rituximab versus immunochemotherapy in patients with R/R DLBCL/HGBL.** EHA 2025;Abstract PS1957.
- Alderuccio JP et al. **Initial results from LOTIS-7: A phase 1b study of loncastuximab tesirine plus glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).** ICML 2025;Abstract 078.

## Phase Ib/II GO29365 Study Final Results: Efficacy

| Outcome*                           | Randomized        |                  | Extension          |
|------------------------------------|-------------------|------------------|--------------------|
|                                    | Pola+BR<br>(n=40) | BR<br>(n=40)     | Pola+BR<br>(n=106) |
| <b>ORR, % (95% CI)</b>             | 42.5 (27.0–59.1)  | 17.5 (7.3–32.8)  | 43.4 (33.8–53.4)   |
| CR, % (95% CI)                     | 42.5 (27.0–59.1)  | 17.5 (7.3–32.8)  | 39.6 (30.3–49.6)   |
| <b>BOR, % (95% CI)</b>             | 62.5 (45.8–77.3)  | 25.0 (12.7–41.2) | 57.5 (47.6–67.1)   |
| BCR, % (95% CI)                    | 52.5 (36.1–68.5)  | 22.5 (10.8–38.5) | 53.8 (43.8–63.5)   |
| <b>Median DOR, months (95% CI)</b> | 10.9 (5.7–40.7)   | 10.6 (4.0–19.7)  | 13.4 (8.6–20.0)    |
| <b>Median PFS, months (95% CI)</b> | 9.2 (6.0–13.9)    | 3.7 (2.1–4.5)    | 7.0 (5.1–9.8)      |
| <b>Median OS, months (95% CI)</b>  | 12.4 (9.0–32.0)   | 4.5 (3.7–6.0)    | 12.3 (8.3–17.0)    |

\*All endpoints were determined by IRC, except OS, which was INV-determined.

BCR, best complete response; BOR, best overall response; BR, bendamustine + rituximab;  
 CI, confidence interval; CR, complete response; DOR, duration of response; INV, investigator;  
 IRC, independent review committee; ORR, overall response rate; OS, overall survival;  
 PFS, progression-free survival; Pola, polatuzumab vedotin.

## Phase Ib/II G029365 Final Results: Safety

|  | Randomized         |               | Extension          |
|--|--------------------|---------------|--------------------|
|  | Pola+BR<br>(n=39*) | BR<br>(n=39*) | Pola+BR<br>(n=106) |
| <b>Any-grade AEs, n (%)</b>                              | 39 (100.0)         | 38 (97.4)     | 105 (99.1)         |
| <b>Grade 3–4 AEs, n (%)</b>                              | 34 (87.2)          | 28 (71.8)     | 83 (78.3)          |
| Neutropenia  | 18 (46.2)          | 13 (33.3)     | 31 (29.2)          |
| Thrombocytopenia   | 15 (38.5)          | 9 (23.1)      | 15 (14.2)          |
| <b>Serious AEs, n (%)</b>                                | 27 (69.2)          | 24 (61.5)     | 57 (53.8)          |
| Pyrexia  | 5 (12.8)           | 0 (0.0)       | 7 (6.6)            |
| Pneumonia  | 4 (10.3)           | 4 (10.3)      | 6 (5.7)            |
| Febrile neutropenia                                      | 4 (10.3)           | 4 (10.3)      | 9 (8.5)            |
| Sepsis   | 2 (5.1)            | 2 (5.1)       | 7 (6.6)            |
| <b>Grade 5 AEs, n (%)</b>                                | 11 (28.2)          | 10 (25.6)     | 6 (5.7)            |
| <b>Any-grade PN, n (%)</b>                               | 17 (43.6)          | 3 (7.7)       | 29 (27.4)          |
| Grade ≥2 PN  | 6 (15.4)           | 2 (5.1)       | 16 (15.1)          |
| <b>AEs leading to delay of any drug, n (%)</b>           | 21 (53.8)          | 14 (35.9)     | 53 (50.0)          |
| <b>AEs leading to discontinuation of any drug, n (%)</b> | 13 (33.3)          | 5 (12.8)      | 16 (15.1)          |

\*One patient in each group did not receive study treatment and so was excluded from the safety-evaluable population.

AE, adverse event; BR, bendamustine + rituximab; PN, peripheral neuropathy; Pola, polatuzumab vedotin.

# Phase III POLARGO Study Design

## Key eligibility criteria

- DLBCL, NOS or history of transformation of indolent disease to DLBCL
- R/R disease after  $\geq 1$  prior line of treatment
- Ineligible for transplant

**Safety run-in**  
Enrolled  $n=15$

**Pola-R-GemOx\***  
Q3W up to 8 cycles

**Primary endpoint**  
Safety and tolerability

**Randomized phase**  
Enrolled  $n=255$

R  
1:1

**Pola-R-GemOx\***  
 $n=129$   
Q3W up to 8 cycles

**Primary endpoint**  
OS


**R-GemOx**  
 $n=126$   
Q3W up to 8 cycles

**Key secondary endpoints**  
PFS (by INV)  
CR<sup>†</sup> (by IRC)  
ORR<sup>†</sup> (by IRC)

## Stratification Factors

- Age ( $\leq 70$  vs  $> 70$  years)
- Prior lines of therapy (1 vs  $\geq 2$ )
- Relapsed vs refractory


# Phase III POLARGO Overall Survival



\*Stratified for age ( $\leq 70$  vs  $> 70$  years), prior lines of systemic therapy (1 vs  $\geq 2$ ), outcome of last systemic therapy (relapsed vs refractory). †Log rank. CI, confidence interval; HR, hazard ratio; NE, not estimable.

# Phase III POLARGO: Progression-Free Survival

Median PFS follow-up: 18.7 months (95% CI: 17.8–23.3)



PFS is censored at earliest subsequent therapy or two or more missing tumor assessments.

\*Stratified for age ( $\leq 70$  vs  $> 70$  years), prior lines of systemic therapy (1 vs  $\geq 2$ ), outcome of last systemic therapy (relapsed vs refractory). †Log rank.

## Phase III POLARGO: Select AEs

| n (%)                                   | Pola-R-GemOx<br>(n=128) | R-GemOx<br>(n=125)     |
|---|-------------------------|------------------------|
| <b>Thrombocytopenia*</b><br>Grade ≥3    | 68 (53.1)<br>44 (34.4)  | 51 (40.8)<br>33 (26.4) |
| <b>Neutropenia*</b><br>Grade ≥3         | 53 (41.4)<br>43 (33.6)  | 52 (41.6)<br>38 (30.4) |
| <b>Febrile neutropenia†</b><br>Grade ≥3 | 3 (2.3)<br>3 (2.3)      | 3 (2.4)<br>3 (2.4)     |
| <b>Anemia*</b><br>Grade ≥3              | 48 (37.5)<br>17 (13.3)  | 35 (28.0)<br>19 (15.2) |
| <b>Infections*</b><br>Grade ≥3          | 53 (41.4)<br>28 (21.9)  | 39 (31.2)<br>12 (9.6)  |
| <b>Hepatic toxicity*</b><br>Grade ≥ 3   | 41 (32.0)<br>11 (8.6)   | 25 (20.0)<br>2 (1.6)   |

\*Custom grouped terms. †Based on preferred term.


# Phase III POLARGO: Peripheral Neuropathy

| n (%), unless otherwise specified                       | Pola-R-GemOx<br>(n=128) | R-GemOx<br>(n=125) |
|---|-------------------------|--------------------|
| <b>Any Grade PN*</b>                                    | 73 (57.0)               | 36 (28.8)          |
| Grade 1   | 48 (37.5)               | 29 (23.2)          |
| Grade 2   | 20 (15.6)               | 7 (5.6)            |
| Grade 3   | 5 (3.9)                 | 0                  |
| <b>Median time to onset, months (range)</b>             | 1.6 (0–8.0)             | 0.9 (0–4.4)        |
| <b>PN AEs leading to any study drug discontinuation</b> | 4 (3.1)                 | 0                  |
| Polatuzumab vedotin discontinuation                     | 3 (2.3)                 | N/A                |
| <b>Number of PN AEs leading to any dose reduction</b>   | 13 (10.2)               | 4 (3.2)            |
| Polatuzumab vedotin reduction                           | 13 (10.2)               | N/A                |
| <b>Patients with all PN AEs resolved or improved</b>    | 37 (50.7)               | 21 (58.3)          |
| Patients with all PN AEs resolved                       | 28 (38.4)               | 21 (58.3)          |

\*Custom grouped terms.

N/A, not applicable; PN, peripheral neuropathy.

# Phase III SUNMO Study Design




\*Administered as an outpatient regimen. †One cycle is 21 days. ‡One cycle is 14 days and may be adjusted to 21 days. §Secondary endpoints include: OS, investigator-assessed PFS, CR rate, ORR, DoR/CR, and time to deterioration of patient-reported outcomes.  
aNHL, aggressive B-cell non-Hodgkin lymphoma; C, cycle; CR, complete response; D, day; DoR, duration of response; Gem, gemcitabine; IV, intravenous; ORR, objective response rate; OS, overall survival; Ox, oxaliplatin; PFS, progression-free survival; R, rituximab; R/R, relapsed/refractory; SC, subcutaneous.


# Phase III SUNMO Primary Results: Overall Response Rate (Primary Endpoint)

| Efficacy Result          | Mosun-Pola (n = 138), (95% CI) | R-GemOx (n = 70), (95% CI) |
|--------------------------|--------------------------------|----------------------------|
| Best overall response    |                                |                            |
| Overall response rate, % | 70 (62 to 78)                  | 40 (28 to 52)              |
| Complete response, %     | 51 (43 to 60)                  | 24 (15 to 36)              |
| Partial response, %      | 19 (13 to 26)                  | 16 (8.1 to 26)             |
| Stable disease, %        | 11 (6.2 to 17)                 | 21 (13 to 33)              |
| Progressive disease, %   | 14 (8.5 to 21)                 | 27 (17 to 39)              |
| Not evaluable, %         | 0                              | 1.4                        |
| Missing or not done, %   | 5.1                            | 10                         |

# Phase III SUNMO Primary Results: PFS (Primary Endpoint)



# Phase III SUNMO Primary Results: OS



| Efficacy Result  | Mosun-Pola (n = 138), (95% CI) | R-GemOx (n = 70), (95% CI) |
|------------------|--------------------------------|----------------------------|
| Overall survival |                                |                            |
| Hazard ratio     | 0.80 (0.5 to 1.2); P = .28     |                            |
| Median, months   | 18.7 (14 to NE)                | 13.6 (9.9 to NE)           |
| 9-month rate, %  | 74 (67 to 82)                  | 67 (55 to 78)              |
| 12-month rate, % | 61 (53 to 70)                  | 53 (41 to 66)              |
| 18-month rate, % | 50 (41 to 59)                  | 43 (31 to 56)              |

## Phase III SUNMO Primary Results: Common AEs

| Adverse Event                       | Mosun-Pola<br>(n = 135), No. (%) |          | R-GemOx<br>(n = 64), No. (%) |          |
|-------------------------------------|----------------------------------|----------|------------------------------|----------|
|                                     | Any Grade                        | Grade ≥3 | Any Grade                    | Grade ≥3 |
| Any adverse event                   | 131 (97)                         | 86 (64)  | 61 (95)                      | 41 (64)  |
| Most common adverse event (≥20%)    |                                  |          |                              |          |
| Injection site reaction             | 71 (53)                          | 0        | 0                            | 0        |
| Neutropenia <sup>a</sup>            | 62 (46)                          | 45 (33)  | 35 (55)                      | 20 (31)  |
| Anemia <sup>a</sup>                 | 41 (30)                          | 8 (5.9)  | 27 (42)                      | 12 (19)  |
| Cytokine response syndrome          | 35 (26)                          | 1 (0.7)  | 0                            | 0        |
| Peripheral neuropathy <sup>b</sup>  | 33 (24)                          | 0        | 27 (42)                      | 0        |
| Fatigue                             | 21 (16)                          | 2 (1.5)  | 13 (20)                      | 1 (1.6)  |
| Nausea                              | 17 (13)                          | 0        | 17 (27)                      | 1 (1.6)  |
| Diarrhea                            | 14 (10)                          | 0        | 15 (23)                      | 1 (1.6)  |
| Thrombocytopenia <sup>a</sup>       | 12 (8.9)                         | 3 (2.2)  | 42 (66)                      | 23 (36)  |
| Infusion-related reaction           | 10 (7.4)                         | 2 (1.5)  | 13 (20)                      | 1 (1.6)  |
| Any treatment-related adverse event | 126 (93)                         | 73 (54)  | 57 (89)                      | 35 (55)  |

# Phase III ECHELON-3 Study Design

## Phase 3 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma


### Key inclusion criteria

- R/R DLBCL with eligible subtypes<sup>a</sup>
- Age  $\geq 18$  years
- $\geq 2$  prior lines of therapy
- **Ineligibility for or disease relapse following HSCT or CAR T-cell therapy**
- ECOG PS 0-2
- FDG-avid, measurable disease

### Key exclusion criteria

- Prior BV or Len
- Active cerebral/meningeal disease
- Grade  $\geq 2$  peripheral neuropathy


- Per protocol, G-CSF prophylaxis was required



HSCT = hematopoietic stem cell transplantation; FDG = fluorodeoxyglucose; ITT = intent to treat; SCT = stem cell transplant

# Phase III ECHELON-3: Overall Survival (Primary Endpoint)

BV+Len+R reduced risk of death by 37% compared with placebo+Len+R




|                                      | <b>BV+Len+R<br/>(n=112)</b> | <b>Placebo+Len+R<br/>(n=118)</b> |
|--------------------------------------|-----------------------------|----------------------------------|
| <b>OS, median</b>                    | <b>13.8</b>                 | <b>8.5</b>                       |
| (95% CI), months                     | (10.3-18.8)                 | (5.4-11.7)                       |
| Hazard ratio (95% CI) <sup>b</sup>   | 0.629 (0.445-0.891)         |                                  |
| Log-rank <i>P</i> value <sup>c</sup> | .0085                       |                                  |
| Events (deaths)                      | 58                          | 76                               |
| Follow-up, median                    | 15.5                        | 18.9                             |
| (95% CI), months                     | (12.2-18.1)                 | (12.2-23.2)                      |

| No. at risk     | 0   | 3  | 6  | 9  | 12 | 15 | 18 | 21 | 24 | 27 | 30 | 33 |
|-----------------|-----|----|----|----|----|----|----|----|----|----|----|----|
| <b>BV+Len+R</b> | 112 | 96 | 79 | 57 | 40 | 30 | 17 | 11 | 5  | 1  | 1  | 0  |
| Placebo+Len+R   | 118 | 81 | 58 | 39 | 28 | 23 | 16 | 12 | 5  | 3  | 0  | 0  |

- BV+Len+R prolonged median OS by 5.3 months compared with placebo+Len+R
- Prespecified O'Brien-Fleming efficacy boundary was crossed at this interim analysis

# Phase III ECHELON-3: PFS (Key Secondary Endpoint)

BV+Len+R reduced risk of disease progression or death by 47% compared with placebo+Len+R




|                                      | <b>BV+Len+R<br/>(n=112)</b> | <b>Placebo+Len+R<br/>(n=118)</b> |
|--------------------------------------|-----------------------------|----------------------------------|
| <b>PFS, median</b>                   | <b>4.2</b>                  | <b>2.6</b>                       |
| (95% CI), months                     | (2.9-7.1)                   | (1.4-3.1)                        |
| Hazard ratio (95% CI) <sup>b</sup>   | 0.527 (0.380-0.729)         |                                  |
| Log-rank <i>P</i> value <sup>c</sup> | <.0001                      |                                  |
| Events                               | 71                          | 85                               |
| Follow-up, median                    | 11.1                        | 8.8                              |
| (95% CI), months                     | (8.6-14.2)                  | (6.9-10.9)                       |

| No. at risk     | 0   | 3  | 6  | 9  | 12 | 15 | 18 | 21 | 24 | 27 | 30 | 33 |
|-----------------|-----|----|----|----|----|----|----|----|----|----|----|----|
| <b>BV+Len+R</b> | 112 | 58 | 38 | 27 | 15 | 11 | 5  | 5  | 2  | 1  | 1  | 0  |
| Placebo+Len+R   | 118 | 40 | 16 | 8  | 4  | 3  | 2  | 2  | 1  | 0  | 0  | 0  |

- PFS was an alpha controlled key secondary endpoint


# Phase III ECHELON-3: Responses

40% CR rate with BV+Len+R and ORR improvement regardless of CD30 expression





- In the total population, the median DOR (95% CI) was longer with BV+Len+R: 8.3 months (4.2-15.3 months) vs 3.0 months (2.8-5.4 months)
  - In patients who had a CR, the median DOR (95% CI) was 18.9 months (11.1 months-NR) with BV+Len+R and NR (2.8 months-NR) with placebo+Len+R
  - The median time to CR onset (range) was 1.58 months (1.2-7.3 months) with BV+Len+R and 1.61 months (0.7-4.6 months) with placebo+Len+R

# Phase III ECHELON-3: Safety




- TEAEs of any grade occurred in 97% of patients with each treatment
- Grade ≥3 TEAEs:
  - 88% with BV+Len+R
  - 77% with placebo+Len+R
  - 9% febrile neutropenia in each group
- Grade 5 TEAEs:
  - 12% with BV+Len+R
  - 8% with placebo+Len+R
- Any grade peripheral neuropathy TEAEs
  - 31% with BV+Len+R
  - 24% with placebo+Len+R
- Relative dose intensity
  - 94.4% for BV
  - 99.7% for placebo


# Loncastuximab Tesirine: A CD19-Directed Antibody-Drug Conjugate



Upon binding to CD19, Loncastuximab tesirine is internalized into the tumor cell and the PBD dimer cytotoxin is released into the cell<sup>1</sup>




PBD dimer—an alkylating agent—binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks<sup>1</sup>



DNA interstrand crosslinks subsequently induce tumor cell death<sup>1</sup>

ADC = antibody-drug conjugate; PBD = pyrrolobenzodiazepine.


# Phase II LOTIS-2 Study: Overall Response Rate (ORR) and Long-Term Responses — All-Treated Population




| Median (range) number of treatment cycles       |             |
|---|-------------|
| All-treated population                          | 3.0 (1-26)  |
| Pts with a CR                                   | 8.0 (1-26)  |
| Pts with a CR, event-free ≥1 year <sup>a</sup>  | 12.5 (1-26) |
| Pts with a CR, event-free ≥2 years <sup>a</sup> | 13.0 (1-22) |

**No new safety signals were identified during the long-term follow-up**


# Phase II LOTIS-2: Progression-Free Survival



# Phase II LOTIS-2: Overall Survival



# Phase III LOTIS-5 Study Design



EOT, end of treatment; Lonca, loncastuximab tesirine; QXW, every X weeks.

## Study Endpoints

- The primary endpoint is progression-free survival (PFS) by independent central review
- Secondary endpoints include OS, overall response rate (ORR), CR rate, duration of response (DOR), safety, PK parameters, Lonca ADAs, and patient-reported outcomes (PROs)
- Exploratory endpoints include correlations between clinical activity and Lonca exposure (ie, Lonca dose and PK metrics) and tumor and/or blood biomarkers

**Efficacy outcomes in safety run-in population (N=20)**

|                             |                  |
|-----------------------------|------------------|
| ORR (95% CI), %             | 80.0 (56.3-94.3) |
| CRR (95% CI), %             | 50.0 (27.2-72.8) |
| Median PFS (95% CI), months | 8.3 (4.5-NE)     |

**Efficacy outcomes in responders (n=16)**

|                             |                |
|-----------------------------|----------------|
| Median DOR (95% CI), months | 8.02 (3.19-NE) |
| Events, n (%)               | 5 (31.3)       |

**Efficacy outcomes in complete responders (n=10)**


|                             |              |
|-----------------------------|--------------|
| Median DOR, months (95% CI) | NE (3.19-NE) |
| Events, n (%)               | 3 (30.0)     |

**MRD results in patients with ctDNA measurements (n=8)**

|   |          |
|---|----------|
| CR and MRD negative, n (%)              | 4 (50.0) |
| MRD negative at end of treatment, n (%) | 4 (50.0) |

CRR, complete response rate; ctDNA, circulating tumor DNA; DOR, duration of response; MRD, minimal residual disease; NE, not estimable; ORR, overall response rate; PFS, progression-free survival.

**Figure 2. Swimmer plot of safety run-in population (N=20)**



Each bar represents one patient in the study. Response is determined by independent reviewer.  
 CR, complete response; MRD, minimal residual disease; NE, not estimable; PD, progressive disease; PR, partial response.


# Phase III LOTIS-5: Efficacy

# Phase III LOTIS-5: Safety

| Safety endpoint, n (%)                     | N=20     |
|--|----------|
| All grade TEAE                             | 20 (100) |
| Grade ≥3 TEAE                              | 11 (55)  |
| GGT increased                              | 5 (25)   |
| Neutropenia                                | 4 (20)   |
| COVID-19/COVID-19 pneumonia                | 3 (15)   |
| Alanine aminotransferase increased         | 1 (5)    |
| Anemia                                     | 1 (5)    |
| Aspartate aminotransferase increased       | 1 (5)    |
| Blood alkaline phosphatase increased       | 1 (5)    |
| Cataract                                   | 1 (5)    |
| Cellulitis gangrenous                      | 1 (5)    |
| Cytomegalovirus infection reactivation     | 1 (5)    |
| Hyponatremia                               | 1 (5)    |
| Malaise                                    | 1 (5)    |
| Neurological decompensation                | 1 (5)    |
| Photosensitivity reaction                  | 1 (5)    |
| Pleural effusion                           | 1 (5)    |
| Tumor lysis syndrome                       | 1 (5)    |
| Urinary tract infection                    | 1 (5)    |
| Serious adverse events                     | 9 (45)   |
| Infection                                  | 6 (30)   |
| Hyponatremia                               | 1 (5)    |
| Anaphylactic reaction                      | 1 (5)    |
| Pleural effusion                           | 1 (5)    |
| Malaise                                    | 1 (5)    |
| Neurological decompression                 | 1 (5)    |
| TEAEs leading to any study drug withdrawal | 8 (40)   |

GGT, gamma-glutamyl transferase; TEAE, treatment-emergent adverse event.

# Phase Ib LOTIS-7 Study Design



## Study population

- Patients with 3L+ R/R B-NHL (part 1) and 2L+ R/R LBCL (part 2)
- ECOG PS score of 0-2
- Prior autologous SCT (>100 days) or CAR-T therapy (>100 days) is allowed
- Measurable disease (per 2014 Lugano Classification)
- Excludes patients with clinically significant third-space fluid accumulation

## Endpoints

- **Primary:** safety and tolerability; MTD and/or RDE
- **Secondary:** ORR, DOR, CR rate, PFS, RFS, and OS; PK and immunogenicity
- **Exploratory:** Glofit concentration in circulation; biomarker and PK correlations with clinical outcomes

# Phase Ib LOTIS-7 Initial Results: Safety Outcomes

## TREATED POPULATION (N=41)

|  | 120 µg/kg <sup>b</sup><br>n=20 | 150 µg/kg <sup>b</sup><br>n=21 | All<br>n = 41     |
|--|--------------------------------|--------------------------------|-------------------|
| <b>Grade 3/4 TEAEs (&gt; 5% of patients)<sup>a</sup></b> | <b>11 (55%)</b>                | <b>12 (57.1%)</b>              | <b>23 (56.1%)</b> |
| Neutropenia  | 4 (20%)                        | 6 (28.6%)                      | 10 (24.4%)        |
| Anemia   | 1 (5%)                         | 3 (14.3%)                      | 4 (9.8%)          |
| AST increased  | 2 (10%)                        | 1 (4.8%)                       | 3 (7.3%)          |
| GGT increase   | 1 (5%)                         | 2 (9.5%)                       | 3 (7.3%)          |
| Thrombocytopenia   | 2 (10%)                        | 1 (4.8%)                       | 3 (7.3%)          |
| <b>Grade 3/4 AESI (all patients)<sup>a</sup></b>         |                                |                                |                   |
| Febrile neutropenia                                      | 0                              | 1 (4.8%)                       | 1 (2.4%)          |
| Thrombocytopenia   | 2 (10%)                        | 1 (4.8%)                       | 3 (7.3%)          |
| GGT increase   | 1 (5%)                         | 2 (9.5%)                       | 3 (7.3%)          |
| Generalized oedema                                       | 1 (5%)                         | 1 (4.8%)                       | 2 (4.9%)          |
| Rash   | 1 (5%)                         | 0                              | 1 (2.4%)          |
| Photosensitivity reaction                                | 0                              | 1 (4.8%)                       | 1 (2.4%)          |
| Sepsis   | 1 (5%)                         | 0                              | 1 (2.4%)          |
| Upper respiratory infection                              | 1 (5%)                         | 0                              | 1 (2.4%)          |
| Pneumonia  | 1 (5%)                         | 0                              | 1 (2.4%)          |
| <b>Serious TEAE</b>                                      | <b>11 (55%)</b>                | <b>9 (42.9%)</b>               | <b>20 (48.8%)</b> |
| <b>No Grade 5 TEAEs occurred</b>                         |                                |                                |                   |

<sup>a</sup>As per Investigator reported adverse events. <sup>b</sup>When the starting dose of Lonca is 120 µg/kg or 150 µg/kg, the dose will be reduced to 75 µg/kg for Cycles ≥3.  
TEAE = treatment emergent adverse event; AESI = adverse event of special interest | Data cutoff: 14 Apr 2025. Data extracted from live clinical database. Data is subject to change.

# Phase Ib LOTIS-7 Initial Results: CRS and ICANS

## TREATED POPULATION (N=41)

|  | 120 µg/kg <sup>b</sup><br>n=20 | 150 µg/kg <sup>b</sup><br>n=21 | All<br>n = 41 |
|--|--------------------------------|--------------------------------|---------------|
| <b>Cytokine Release Syndrome<sup>a</sup></b> |                                |                                |               |
| Any grade                                    | 11 (55%)                       | 5 (23.8%)                      | 16 (39.0%)    |
| Grade 1                                      | 7 (35%)                        | 5 (23.8%)                      | 12 (29.3%)    |
| Grade 2                                      | 3 (15%)                        | 0                              | 3 (7.3%)      |
| Grade 3                                      | 1 (5%)                         | 0                              | 1 (2.4%)      |
| Grade 4/5                                    | 0                              | 0                              | 0             |
| <b>ICANS<sup>a</sup></b>                     |                                |                                |               |
| Any grade                                    | 2 (10%)                        | 1 (4.8%)                       | 3 (7.3%)      |
| Grade 1                                      | 1 (5%)                         | 0                              | 1 (2.4%)      |
| Grade 2                                      | 1 (5%)                         | 1 (4.8%)                       | 2 (4.9%)      |
| Grade ≥ 3                                    | 0                              | 0                              | 0             |

Any-grade CRS was less frequent at the Lonca 150 µg/kg starting dose<sup>b</sup> (23.8%) than at 120 µg/kg starting dose<sup>b</sup> (55.0%)

- Grade 1 and 2 CRS cases managed with tocilizumab, corticosteroids, acetaminophen, and/or fluid bolus, without ICU admittance or pressor support
- Grade 3 CRS case managed with tocilizumab, acetaminophen, dexamethasone, norepinephrine. ICU admittance

- All patients with ICANS had complete resolution of symptoms
  - Two patients resumed treatment and ultimately achieved a CR
  - One patient elected to discontinue treatment
- ICANS managed primarily with corticosteroids

<sup>a</sup>Number of patients who experienced at least 1 event per ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells; worst grade reported if applicable


<sup>b</sup>When the starting dose of Lonca is 120 µg/kg or 150 µg/kg, the dose will be reduced to 75 µg/kg for Cycles ≥3.

Data Cutoff 14 Apr 2025. Data extracted from live clinical database. Data is subject to change.

# Phase Ib LOTIS-7 Initial Results: Best Overall Responses, DoR

## EFFICACY EVALUABLE POPULATION (N=30)<sup>a</sup>

### Best overall response<sup>b</sup>



### Duration of response


| Characteristic, n (%)                                 | Glofit + Lonca, 120 µg/kg <sup>c</sup> (n=15) | Glofit + Lonca, 150 µg/kg <sup>c</sup> (n=15) | All dose levels (N=30) |
|---|---|---|------------------------|
| <b>DOR<sup>d</sup> Median</b>                         | (n=14)<br>NE                                  | (n=14)<br>NE                                  | (n=28)<br>NE           |
| <b>Time to first response (CR or PR) Median, days</b> | (n=14)<br>42.0                                | (n=14)<br>42.0                                | (n=28)<br>42.0         |
| <b>Time to first CR Median, days</b>                  | (n=13)<br>80.0                                | (n=13)<br>42.0                                | (n=26)<br>70.5         |

Data cutoff: April 14, 2025.

CR, complete response; DOR, duration of response; Glofit, glofitamab; Lonca, loncastuximab tesirine; NE, not estimable; ORR, overall response rate; PR, partial response.

<sup>a</sup>The efficacy evaluable population (N=30) included all patients who received ≥1 dose of the study drug with a valid baseline and ≥1 valid postbaseline disease assessment. Patients who did not have a postbaseline assessment owing to early clinical progression or death were also included. <sup>b</sup>Percentages do not add up to total due to rounding. <sup>c</sup>When the starting dose of Lonca is 120 µg/kg or 150 µg/kg, the dose will be reduced to 75 µg/kg for Cycles ≥3. <sup>d</sup>In the efficacy evaluable population, the DOR and probability of maintaining an event-free response were evaluated in responders (n=28), including all patients who had a best response of CR or PR.

# Phase Ib LOTIS-7 Initial Results: Efficacy over Time



# Updated Data Announced from LOTIS-7 Phase 1b Trial of Loncastuximab Tesirine in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen for R/R DLBCL

Press Release: December 3, 2025

“On December 3, 2025, [the manufacturer] announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of loncastuximab tesirine in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The updated data is based on investigator assessment and reflects the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up from treatment initiation.

Enrollment in the LOTIS-7 clinical trial is ongoing, with complete enrollment of approximately 100 patients at the selected 150 µg/kg dose expected during the first half of 2026. The Company plans to share full data at a medical meeting and submit for publication by the end of 2026. In addition, the Company plans to assess regulatory and compendia strategies.”

# Optimizing the Use of Novel Therapies for Patients with DLBCL

**Module 1: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)**

**Module 2: Clinician Survey Results**









**Module 3: Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL**

**Module 4: Clinician Survey Results**

**Module 5: Evidence-Based Incorporation of Antibody-Drug Conjugates into the Management of R/R DLBCL**









**Module 6: Clinician Survey Results**

# Outside of a clinical trial, would you partner polatuzumab vedotin with other systemic therapies beyond BR for patients with R/R DLBCL under any circumstances?

|   |   |
|---|---|
|  Dr Abramson   | Yes, mosunetuzumab and glofitamab                 |
|  Dr Kahl       | Yes, mosunetuzumab                                |
|  Dr Kamdar     | Yes, mosunetuzumab and glofitamab                 |
|  Dr LaCasce    | Yes, mosunetuzumab and glofitamab                 |
|  Dr Matasar    | Yes, R-GemOx, R-ICE, mosunetuzumab and glofitamab |
|  Dr Phillips   | Yes, mosunetuzumab and glofitamab                 |
|  Prof Salles | Yes, mainly glofitamab                            |
|  Dr Westin   | Yes, mosunetuzumab                                |









R-ICE = rituximab/ifosfamide/carboplatin/etoposide

## Where in the treatment course do you typically employ loncastuximab tesirine for your patients with R/R DLBCL? Would you administer it to a patient who has experienced disease progression on one or more other CD19-directed approaches?









|  | When  | After PD on other CD19-directed tx?           |
|--|---|---|
|  <b>Dr Abramson</b>   | After CAR T and BsAb therapies  | Yes, but only after assessing CD19 expression |
|  <b>Dr Kahl</b>       | After BsAb failure  | Yes, but only after assessing CD19 expression |
|  <b>Dr Kamdar</b>     | After CAR T and BsAb therapies  | Yes, but only after assessing CD19 expression |
|  <b>Dr LaCasce</b>    | After CD20 BsAb therapy   | Yes, but only after assessing CD19 expression |
|  <b>Dr Matasar</b>    | 3L+ especially post-CAR T with residual CD19+                             | Yes, but only after assessing CD19 expression |
|  <b>Dr Phillips</b>  | 3L+, after PD on CAR T (early relapse) or BsAb (late relapse after CAR T) | Yes, but only after assessing CD19 expression |
|  <b>Prof Salles</b> | When first-line, CAR T and bispecific Ab treatments have failed           | Yes, but only after assessing CD19 expression |
|  <b>Dr Westin</b>   | If CAR T ineligible and unable/unwilling/relapsed after BsAb              | Yes, but only after assessing CD19 expression |

PD = disease progression; BsAb = bispecific antibody

Approximately what proportion of your patients with R/R DLBCL receiving loncastuximab tesirine derive meaningful clinical benefit? What is the longest duration of response that you have observed with loncastuximab tesirine in your own practice?









|   | Patients with clinical benefit | Longest duration of response |
|---|--------------------------------|------------------------------|
|  Dr Abramson   | 30%                            | >1 year                      |
|  Dr Kahl       | 40%                            | About 1 year                 |
|  Dr Kamdar     | 20%                            | 9 months                     |
|  Dr LaCasce    | 10%                            | 3 months                     |
|  Dr Matasar    | 50%                            | 4 years+                     |
|  Dr Phillips  | 30%                            | >1 year                      |
|  Prof Salles | 30%                            | 6 months                     |
|  Dr Westin   | 45%                            | >1 year                      |

Approximately what proportion of your patients with DLBCL receiving loncastuximab tesirine develop clinically significant peripheral edema? In general, how do you manage peripheral edema in patients who are receiving loncastuximab tesirine?

|  | Patients with significant peripheral edema | Management  |
|--|--|---|
|  <b>Dr Abramson</b>   | 25%  | Dexamethasone prophylaxis, diuretics                                  |
|  <b>Dr Kahl</b>       | 60%  | Stop drug; diuretics  |
|  <b>Dr Kamdar</b>     | 30%  | Dexamethasone prophylaxis, diuretics                                  |
|  <b>Dr LaCasce</b>    | 20%  | Peri-drug dexamethasone per label, diuretics                          |
|  <b>Dr Matasar</b>    | 25%  | Diuretics   |
|  <b>Dr Phillips</b>  | 50%  | Initiate preventative diuretic in most patients, hold/stop drug if AE |
|  <b>Prof Salles</b> | 20%  | Diuretic and prophylactic steroids, then diuretic alone               |
|  <b>Dr Westin</b>   | 33%  | Diuretics and steroids  |

AE = adverse event

# Would you administer brentuximab vedotin/R<sup>2</sup> to a patient with CD30-negative R/R DLBCL?

|   |             |     |
|---|-------------|-----|
|    | Dr Abramson | Yes |
|    | Dr Kahl     | No  |
|    | Dr Kamdar   | Yes |
|    | Dr LaCasce  | No  |
|    | Dr Matasar  | No  |
|    | Dr Phillips | No  |
|  | Prof Salles | No  |
|  | Dr Westin   | No  |

R<sup>2</sup> = lenalidomide/rituximab

**Questions?**